九洲藥業(603456.SH)近期股票漲幅較大提示風險 與吉利德未就新型冠狀病毒肺炎在研藥物瑞德西韋開展實質性合作
格隆匯2月5日丨九洲藥業(603456.SH)公佈,公司A股股票於2020年2月3日、2月4日連續兩個交易日收盤價格漲幅偏離值累計達到20%以上,公司已於2020年2月5日披露了《股票交易異常波動公告》。2020年2月5日公司股票漲停。鑑於近期公司股票波動較大,現對公司有關事項和風險説明如下:
一、公司當前市盈率明顯高於行業水平
根據中國證監會發布的行業分類結果,公司所處行業為醫藥製造業。經查詢中證指數有限公司官網,截至2020年2月5日收盤,公司滾動市盈率為83.22倍,醫藥製造業的滾動市盈率為37.50倍。敬請廣大投資者注意二級市場交易風險,理性決策,審慎投資。
二、媒體報道、市場傳聞、熱點概念風險提示
近日,上證E互動平台有投資者關注公司合作、產品等情況,現就相關情況做如下説明:
公司與吉利德公司於2011年開始合作,公司已為其提供多個品種的醫藥中間體CDMO服務,近兩年,吉利德公司的產品銷售收入佔公司營業收入不超過2%。截止公告日,雙方未就新型冠狀病毒肺炎在研藥物Remdesivir(瑞德西韋)開展實質性合作,敬請廣大投資者注意投資風險。
三、公司子公司復產風險
公司子公司江蘇瑞科醫藥科技有限公司(“江蘇瑞科”)因園區唯一供熱接入點停止對外供熱,目前為停產狀態。具體內容詳見公司相關公告。截止公告日,江蘇瑞科復產時間尚未確定,可能會對公司業績產生一定影響。敬請廣大投資者注意投資風險。
四、公司產品結構、主營業務未發生重大變化
公司目前經營狀況正常,內外部經營環境未發生重大變化,目前產品結構和主營業務均未發生重大變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.